Filing Flows › TherapeuticsMD (TXMD) › Q3 2025
TherapeuticsMD (TXMD) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
TherapeuticsMD (TXMD) reported revenue of $784K for the third quarter 2025 (Q3 2025), +43% from a year earlier and -18% from the quarter before. Operating margin was -109.9%, net earnings $152K (19.4% of revenue).
TherapeuticsMD, Q3 2025: revenue $784K (+43% year over year), operating margin -109.9%, net earnings $152K, operating cash flow $999K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $784K | -18% | +43% |
| Operating profit | −$862K | — | — |
| Net earnings | $152K | -72% | — |
| Operating cash flow | $999K | +162% | — |
What changed
Revenue was $784K in Q3 2025, up 43% year over year and down 18% from the previous quarter.
Operating costs exceeded revenue by $862K, an operating margin of -109.9%. Total costs fell 2% while revenue rose 43%. The fastest-growing cost line was Other operating costs (+33%). Net earnings were $152K. The effective tax rate was 0.0%. Non-operating items added $1.0M, 667% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $1.0M, 657% of net earnings. Non-cash charges added back $96K of depreciation and amortization. Working capital and other items added $751K.
Questions
What was TherapeuticsMD's revenue in the third quarter 2025?
TherapeuticsMD (TXMD) reported revenue of $784K for the third quarter 2025 (Q3 2025), +43% from a year earlier and -18% from the quarter before.
Was TherapeuticsMD profitable in the third quarter 2025?
Operating loss was $862K (-109.9% of revenue) and net earnings $152K.
Source: TherapeuticsMD 10-Q on SEC EDGAR.